Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease

The New England Journal of Medicine
A Michael LincoffACCELERATE Investigators

Abstract

The cholesteryl ester transfer protein inhibitor evacetrapib substantially raises the high-density lipoprotein (HDL) cholesterol level, reduces the low-density lipoprotein (LDL) cholesterol level, and enhances cellular cholesterol efflux capacity. We sought to determine the effect of evacetrapib on major adverse cardiovascular outcomes in patients with high-risk vascular disease. In a multicenter, randomized, double-blind, placebo-controlled phase 3 trial, we enrolled 12,092 patients who had at least one of the following conditions: an acute coronary syndrome within the previous 30 to 365 days, cerebrovascular atherosclerotic disease, peripheral vascular arterial disease, or diabetes mellitus with coronary artery disease. Patients were randomly assigned to receive either evacetrapib at a dose of 130 mg or matching placebo, administered daily, in addition to standard medical therapy. The primary efficacy end point was the first occurrence of any component of the composite of death from cardiovascular causes, myocardial infarction, stroke, coronary revascularization, or hospitalization for unstable angina. At 3 months, a 31.1% decrease in the mean LDL cholesterol level was observed with evacetrapib versus a 6.0% increase with pla...Continue Reading

Associated Clinical Trials

References

Jul 4, 2001·JAMA : the Journal of the American Medical Association·M A AlbertUNKNOWN PRINCE Investigators
Feb 18, 2003·Arteriosclerosis, Thrombosis, and Vascular Biology·Philip J BarterAlan R Tall
Mar 10, 2004·The New England Journal of Medicine·Christopher P CannonUNKNOWN Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators
Sep 1, 2004·JAMA : the Journal of the American Medical Association·James A de LemosUNKNOWN Investigators
Mar 10, 2005·The New England Journal of Medicine·John C LaRosaUNKNOWN Treating to New Targets (TNT) Investigators
Oct 4, 2005·Journal of the American College of Cardiology·Peter Libby
Mar 15, 2006·The New England Journal of Medicine·Deepak L BhattUNKNOWN CHARISMA Investigators
Sep 28, 2007·The New England Journal of Medicine·Philip BarterUNKNOWN Treating to New Targets Investigators
Nov 6, 2007·The New England Journal of Medicine·Stephen D WiviottUNKNOWN TRITON-TIMI 38 Investigators
Nov 7, 2007·The New England Journal of Medicine·Philip J BarterUNKNOWN ILLUMINATE Investigators
Feb 2, 2008·Nature Reviews. Drug Discovery·Tisha Joy, Robert A Hegele
Jun 19, 2008·JAMA : the Journal of the American Medical Association·Alexander ThompsonJohn Danesh
Nov 11, 2008·The New England Journal of Medicine·Paul M RidkerUNKNOWN JUPITER Study Group
Sep 1, 2009·The New England Journal of Medicine·Lars WallentinMona Thorsén
Nov 7, 2012·The New England Journal of Medicine·Gregory G SchwartzUNKNOWN dal-OUTCOMES Investigators
Jan 30, 2014·European Heart Journal·Michael V HolmesJuan P Casas
Nov 19, 2014·The New England Journal of Medicine·Anand RohatgiPhilip W Shaul
Jun 4, 2015·The New England Journal of Medicine·Christopher P CannonUNKNOWN IMPROVE-IT Investigators
Sep 2, 2015·Nature Reviews. Cardiology·Robert S RosensonNancy R Webb
Nov 14, 2015·Journal of the American College of Cardiology·Stephen J NichollsDaniel J Rader

❮ Previous
Next ❯

Citations

Jun 2, 2017·Nature Reviews. Cardiology·Irene Fernández-Ruiz
Sep 30, 2017·Diseases·Theodosios D FilippatosMoses S Elisaf
Feb 8, 2018·Journal of Cardiovascular Pharmacology and Therapeutics·Theodosios D FilippatosMoses S Elisaf
Dec 10, 2017·Diabetes Care·UNKNOWN American Diabetes Association
Jan 23, 2018·Current Opinion in Lipidology·Andrea VoltaAldo Grefhorst
Mar 1, 2018·Journal of Lipid Research·Sudichhya ShresthaKerry-Anne Rye
Nov 6, 2017·Current Cardiology Reports·Cecilia VitaliDaniel J Rader
Aug 11, 2017·Nature Reviews. Cardiology·Robert S RosensonRobert A Hegele
Dec 26, 2017·Hospital Pharmacy·Jerry Hu, Scot Walker
Sep 9, 2017·Expert Review of Clinical Pharmacology·Georgios Polychronopoulos, Konstantinos Tziomalos
Mar 22, 2018·Current Opinion in Cardiology·Anthony S WierzbickiAdie Viljoen
Jun 15, 2018·Clinical Pharmacology and Therapeutics·Stephen J Nicholls
Jul 3, 2018·Journal of Diabetes·Sergio Fazio, Michael D Shapiro
Jun 8, 2018·Current Opinion in Lipidology·Valentina RodriguezArthur Z Schwartzbard
Apr 10, 2018·Current Opinion in Lipidology·Sheila A Doggrell
Jun 22, 2018·JAMA Cardiology·Stephen BurgessUNKNOWN European Prospective Investigation Into Cancer and Nutrition–Cardiovascular Disease (EPIC-CVD) Consortium
Nov 14, 2017·European Journal of Clinical Investigation·Luca LiberaleAldo Bonaventura
Aug 24, 2017·Praxis·Arnold von Eckardstein
Oct 12, 2017·Circulation Research·Alan R Tall, Daniel J Rader
Feb 23, 2018·Arteriosclerosis, Thrombosis, and Vascular Biology·Christian M Madsen, Børge G Nordestgaard
Oct 27, 2018·Nature Reviews. Nephrology·Charles J FerroCarmine Zoccali
Dec 14, 2018·Journal of Atherosclerosis and Thrombosis·Ryuji Toh
Dec 26, 2018·Arteriosclerosis, Thrombosis, and Vascular Biology·Steven SheaAlan R Tall
Dec 21, 2018·Arteriosclerosis, Thrombosis, and Vascular Biology·Jeremy D FurtadoFrank M Sacks
Jan 25, 2019·Cardiovascular Drugs and Therapy·Scott T Chiesa, Marietta Charakida
Feb 1, 2019·Circulation·Emelia J BenjaminUNKNOWN American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee
Feb 1, 2019·Circulation Research·Robert A Hegele, Sotirios Tsimikas
Jan 17, 2019·Current Opinion in Lipidology·Mark TrinderLiam R Brunham
Mar 15, 2019·Current Cardiology Reports·Mathieu KerneisC Michael Gibson
Oct 16, 2018·American Journal of Respiratory and Critical Care Medicine·Mark TrinderLiam R Brunham
Apr 5, 2019·Journal of Atherosclerosis and Thrombosis·Akemi KakinoTatsuya Sawamura
Apr 20, 2019·Diabetes, Obesity & Metabolism·Hanney Gonna, Kausik K Ray
Apr 20, 2019·Diabetes, Obesity & Metabolism·Satya Dash, Lawrence A Leiter

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Biomarkers for Cardiovascular Risk Assessment

Sensitive and accurate biomarkers used in cardiovascular risk prediction can potentially be used to manage the risk of cardiovascular disease. Discover the latest research on Biomarkers for Cardiovascular Risk Assessment here. Discover the latest research on Biomarkers for Cardiovascular Risk Assessment here.

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

Carotid Artery Diseases

Carotid artery disease is a group of pathological conditions of the carotid artery. Discover the latest research on carotid artery disease here.

Related Papers

The New England Journal of Medicine
Marc S SabatineFOURIER Steering Committee and Investigators
The New England Journal of Medicine
Christopher P CannonDetermining the Efficacy and Tolerability Investigators
The New England Journal of Medicine
Christopher P CannonIMPROVE-IT Investigators
© 2022 Meta ULC. All rights reserved